Production of differentiated enteroendocrine cells and insulin producing cells
A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.
1. A method for obtaining a population of enteroendocrine cells (EECs) from mammalian LGR5 positive epithelial stem cells, the method comprising:
a) adding the LGR5 positive epithelial stem cells to a cell culture medium comprising a Notch inhibitor and a Wnt activator to form a first resultant cell population; and
b) adding the first resultant cell population to a cell culture medium comprising a Notch inhibitor and at least one of an EGFR inhibitor and a MEK/ERK inhibitor without a Wnt activator, thereby forming a population of EECs.
2. The method of claim 1 , wherein the Wnt activator is R-Spondin1, the Notch inhibitor is N—[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) or a pharmaceutically acceptable salt thereof, and the MEK/ERK inhibitor is N-[(2R)-2,3-Dihydroxypropoxyl]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the cell culture medium of b) further comprises a Wnt inhibitor.
4. The method of claim 3 , wherein the Wnt inhibitor comprises a compound having the following structure:
5. The method of claim 1 , wherein the cell culture medium of a) further comprises at least one of epidermal growth factor (EGF) and Noggin, or wherein the cell culture medium of b) further comprises at least one of EGF or Noggin.
6. The method of claim 1 , wherein the cell culture medium of a) further comprises at least one of a histone deacetylase (HDAC) inhibitor, a Histone Methylation Inhibitor, and a Ca2+/NeuroD1 activator, or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the cell culture medium of a) further comprises at least one of Tubastatin A, tranylcypromine and N-cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide, or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein:
the cell culture medium of a) further comprises a TGF-β inhibitor or a pharmaceutically acceptable salt thereof; or
the cell culture medium of b) further comprises a TGF-β inhibitor or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the cell culture medium of b) further comprises a compound having the following structure:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 wherein the cell culture medium of b) further comprises a histone methylation inhibitor, or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the cell culture medium of b) further comprises tranylcypromine, or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the first resultant cell population exhibits increased Neurogenin-3 expression compared to the LGR5 positive epithelial stem cells, and the population of EECs exhibits decreased Neurogenin-3 expression compared to the first resultant cell population.
13. The method of claim 1 , wherein the mammalian LGR5 positive epithelial stem cells comprise at least one of stomach stem cells, intestinal stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells, and neural stem cells.
14. The method of claim 13 , wherein the mammalian LGR5 positive epithelial stem cells are intestinal stem cells.
15. A method for obtaining a population of enteroendocrine cells (EECs) from mammalian LGR5 positive epithelial stem cells, the method comprising:
a) adding the LGR5 positive epithelial stem cells to a cell culture medium comprising a Notch inhibitor and a Wnt activator to form a first resultant cell population; and
b) adding the first resultant cell population to a cell culture medium comprising a Notch inhibitor without a Wnt activator, thereby forming a population of EECs.
16. The method of claim 15 , wherein the Wnt activator is R-Spondin1, and the Notch inhibitor is N—[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) or a pharmaceutically acceptable salt thereof.
17. The method of claim 15 , wherein the cell culture medium of b) further comprises a Wnt inhibitor.
18. The method of claim 17 , wherein the Wnt inhibitor comprises a compound having the following structure:
19. The method of claim 15 , wherein the cell culture medium of a) further comprises at least one of epidermal growth factor (EGF) and Noggin, or wherein the cell culture medium of b) further comprises at least one of EGF or Noggin.
20. The method of claim 15 , wherein the cell culture medium of a) further comprises at least one of a histone deacetylase (HDAC) inhibitor, a Histone Methylation Inhibitor, and a Ca2+/NeuroD1 activator, or a pharmaceutically acceptable salt thereof.
21. The method of claim 20 , wherein the cell culture medium of a) further comprises at least one of Tubastatin A, tranylcypromine and N-cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide, or a pharmaceutically acceptable salt thereof.
22. The method of 15 , wherein the cell culture medium of b) further comprises a TGF-β inhibitor or a pharmaceutically acceptable salt thereof.
23. The method of claim 22 , wherein the cell culture medium of b) further comprises a compound having the structure:
or a pharmaceutically acceptable salt thereof.
24. The method of claim 15 wherein the cell culture medium of b) further comprises a histone methylation inhibitor or a pharmaceutically acceptable salt thereof.
25. The method of claim 24 , wherein the cell culture medium of b) further comprises tranylcypromine or a pharmaceutically acceptable salt thereof.
26. The method of claim 15 , wherein the first resultant cell population exhibits increased Neurogenin-3 expression compared to the LGR5 positive epithelial stem cells, and the population of EECs exhibits decreased Neurogenin-3 expression compared to the first resultant cell population.
27. The method of claim 15 , wherein the mammalian LGR5 positive epithelial stem cells comprise at least one of stomach stem cells, intestinal stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells, and neural stem cells.
28. The method of claim 27 , wherein the mammalian LGR5 positive epithelial stem cells are intestinal stem cells.
29. The method of claim 15 , wherein the cell culture medium of b) further comprises an MEK/ERK inhibitor, wherein the MEK/ERK inhibitor is N-[(2R)-2,3-Dihydroxypropoxyl]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide.